Olfactory Hallucinations as a Clinical Marker in Neurological Pathologies: Pathophysiology and Diagnostic Considerations

Emma Thomas*

Department of Neurology, University of Edinburgh, Edinburgh, Scotland, UK

Commentary

Received: 26-Dec-2024, Manuscript No. Neuroscience-24-156720; **Editor assigned:** 31-Dec-2024, Pre QC No. Neuroscience-24-156720 (PQ); **Reviewed:** 14-Jan-2025, QC No. Neuroscience-24-156720; **Revised:** 09-Mar-2026, Manuscript No. Neuroscience-24-156720 (R); **Published:** 16-Mar-2026, DOI: 10.4172/rrns.10.005

***For Correspondence:** Emma Thomas, Department of Neurology, University of Edinburgh, Edinburgh, Scotland, UK;
E-mail: emma.thomas@neurology.ed.ac.uk

Citation: Thomas E. Olfactory Hallucinations as a Clinical Marker in Neurological Pathologies: Pathophysiology and Diagnostic Considerations. RRJ Neuroscience. 2026;10:005.

DESCRIPTION

Olfactory hallucinations, or phantosmia, are the perception of smells that are not present in the external environment. They are often considered a clinical marker for several neurological pathologies, including epilepsy, Parkinson's disease, and various neurodegenerative disorders. Olfactory hallucinations are abnormal sensory experiences that occur when individuals perceive smells that do not exist. These hallucinations can be distressing, and their presence often signals underlying neurological dysfunction. Phantosmia can manifest in various forms, including pleasant, neutral, or unpleasant smells, and its etiology is diverse. Understanding the pathophysiology of olfactory hallucinations and their role in diagnosing neurological conditions is crucial for accurate diagnosis and effective management.

Pathophysiology of olfactory hallucinations

Neurological lesions: Damage to the olfactory bulb, the temporal lobe, or the limbic system can result in olfactory hallucinations. In particular, lesions in the piriform cortex and the orbitofrontal cortex, areas involved in olfactory processing, have been implicated in the development of phantosmia.

Neurodegenerative diseases: Disorders such as Alzheimer's disease and Parkinson's disease are frequently associated with olfactory dysfunction, including olfactory hallucinations. In these conditions, changes in brain regions responsible for olfactory processing contribute to the development of phantom smells.

Epilepsy: Olfactory hallucinations are commonly reported as part of an aura in patients with temporal lobe epilepsy. The seizures often arise from the limbic system, which includes structures involved in both memory and olfactory processing.

Neurochemical imbalance: Dysregulation of neurotransmitters such as dopamine, serotonin, and glutamate in the brain may also contribute to the occurrence of olfactory hallucinations. This imbalance is particularly evident in neurodegenerative diseases and psychiatric disorders.

Diagnostic considerations

Patient history and clinical evaluation: A comprehensive history that includes the onset, frequency, and nature of the olfactory hallucinations, along with other neurological symptoms, is essential. Detailed questioning about possible triggers such as seizures, head trauma, or recent infections is important.

Neuroimaging: Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) scans can reveal structural or functional abnormalities in the olfactory pathways. Imaging studies are particularly useful in identifying lesions in the olfactory bulb, temporal lobes, or limbic system.

Electroencephalography (EEG): For patients with suspected epilepsy, EEG can help identify seizure activity that may be contributing to olfactory hallucinations, especially in cases of temporal lobe epilepsy.

Neuropsychological testing: Cognitive assessments can help identify early signs of neurodegeneration, especially in the context of Alzheimer's and Parkinson's diseases, where olfactory dysfunction is a common early symptom.